Diadema Partners’s Passage Bio PASG Stock Holding History

Diadema Partners’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,530	Closed	-$153K	–	185
2026 Q1	$153K	Buy	+19,530	New	+$202K	0.03%	127

Other funds holding PASG

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

YCM

Yiheng Capital Management San Francisco, California $291M AUM 19.43% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verdad Advisers Boston, Massachusetts $104M AUM

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Diadema Partners's PASG Position: Q2 2026 in Review

Diadema Partners sold out of Passage Bio (PASG) in Q2 2026, closing a stake of 19,530 shares — an estimated $153K sold.

Diadema Partners first reported a position in PASG in Q1 2026 and held it in 1 quarter. The position peaked at $153K in Q1 2026. 29 funds tracked by Wall St. Rank hold PASG as of Q2 2026.

Diadema Partners reported no remaining Passage Bio position as of Q2 2026 after selling out during the quarter.
Diadema Partners sold 19,530 Passage Bio shares in Q2 2026, an estimated $153K.
Diadema Partners first reported a position in Passage Bio in Q1 2026 and held it in 1 quarter.
Diadema Partners's Passage Bio position peaked at $153K in Q1 2026.
29 funds tracked by Wall St. Rank held Passage Bio as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.